Atom Investors LP Acquires Shares of 77,733 Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Atom Investors LP bought a new position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 77,733 shares of the biopharmaceutical company’s stock, valued at approximately $122,000.

Several other institutional investors have also recently made changes to their positions in LXRX. CVI Holdings LLC purchased a new stake in Lexicon Pharmaceuticals in the second quarter worth $34,000. Principal Financial Group Inc. grew its position in shares of Lexicon Pharmaceuticals by 116.1% in the 2nd quarter. Principal Financial Group Inc. now owns 22,759 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 12,225 shares during the period. Great Point Partners LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter worth about $50,000. BNP Paribas Financial Markets increased its stake in shares of Lexicon Pharmaceuticals by 71.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 31,853 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 13,246 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its position in Lexicon Pharmaceuticals by 44.5% during the 2nd quarter. Victory Capital Management Inc. now owns 45,341 shares of the biopharmaceutical company’s stock valued at $76,000 after acquiring an additional 13,972 shares during the period. Institutional investors own 74.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Friday, November 22nd. Leerink Partners set a $6.00 price objective on Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research report on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Lexicon Pharmaceuticals in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Lexicon Pharmaceuticals has a consensus rating of “Hold” and an average target price of $6.00.

Lexicon Pharmaceuticals Trading Down 5.1 %

Shares of NASDAQ LXRX opened at $0.65 on Friday. The firm’s 50 day moving average price is $1.38 and its 200-day moving average price is $1.64. Lexicon Pharmaceuticals, Inc. has a 52-week low of $0.62 and a 52-week high of $3.73. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45. The company has a market cap of $160.06 million, a PE ratio of -0.87 and a beta of 1.07.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The business had revenue of $1.75 million for the quarter, compared to analysts’ expectations of $3.14 million. During the same quarter in the prior year, the business posted ($0.21) earnings per share. On average, equities research analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.